… Despite this great progress, there remain great unmet needs for patients whose tumors harbor
BRAF mutations with respect to BRAF inhibition. First and foremost, therapeutic resistance …

… in BRAF-mutant melanoma could be really important to improve patients’ outcome. … In
order to better understand the biology underlying the principle mechanisms involved in BRAF …

… harboring activating BRAF V600E mutations and are … mutated BRAF in the development
and progression of melanoma as the basis for understanding the mechanism of action of BRAF …

… have been reported as a rare resistance mechanism to BRAF + MEK inhibitors in class I
BRAF mutant melanoma, as well as in 0.6–1% of pancreatic/thyroid tumors [51,52,53]. Such …

… the mechanisms underlying the efficacy of BRAF inhibitors in … MAPK pathway, and
BRAF-activating mutations are found in … mutation which accounts for 80–90% of BRAF mutations …

… mechanism. This is convincingly shown for the tumor cells that express mutant NRAS in
the context of mutant BRAF. NRAS knockdown sensitized these tumors to RAF inhibition ( …

… different profile from BRAF-inhibitors with a slow action and an … b BRAF mutant melanoma
patients with high-dose IL-2 or ipilimumab. The reasons for this lie in the mechanisms of action …

… of BRAF V600E-driven signalling). This blockade is associated with reduction in Cyclin D1
expression and downregulation of proliferation. That the BRAF mutation … of the BRAF V600E-…

… Small molecule BRAF inhibitors developed specifically to target BRAF V600E have proven …
dominant BRAF mutant in melanomas, but are less potent against other BRAF mutants in RAS…

… BRAF mutation, others, within the same patient, may carry different mutations not susceptible
to BRAF … Whilst the mechanisms by which mutant BRAF induces immunogenicity are …